China Biologic Products Inc (CBPO) : Dymon Asia Capital Ltd has sold out all of its stake in China Biologic Products Inc during the most recent quarter, according to the disclosure filed by the company on Aug 12, 2016 with the SEC. The investment management company has sold out 8,000 shares of China Biologic Products Inc which is valued at $1,005,120.
Other Hedge Funds, Including , Renaissance Technologies reduced its stake in CBPO by selling 140,700 shares or 38.06% in the most recent quarter. The Hedge Fund company now holds 229,000 shares of CBPO which is valued at $28,771,560. China Biologic Products Inc makes up approx 0.05% of Renaissance Technologies’s portfolio.Credit Agricole S A boosted its stake in CBPO in the latest quarter, The investment management firm added 12,718 additional shares and now holds a total of 80,470 shares of China Biologic Products Inc which is valued at $10,110,251. China Biologic Products Inc makes up approx 0.04% of Credit Agricole S A’s portfolio.Blackrock Group Ltd reduced its stake in CBPO by selling 89,420 shares or 26.23% in the most recent quarter. The Hedge Fund company now holds 251,433 shares of CBPO which is valued at $31,590,042. China Biologic Products Inc makes up approx 0.02% of Blackrock Group Ltd’s portfolio.Gsa Capital Partners Llp boosted its stake in CBPO in the latest quarter, The investment management firm added 1,320 additional shares and now holds a total of 41,815 shares of China Biologic Products Inc which is valued at $5,610,319. China Biologic Products Inc makes up approx 0.29% of Gsa Capital Partners Llp’s portfolio.Navellier Associates Inc reduced its stake in CBPO by selling 204 shares or 5.44% in the most recent quarter. The Hedge Fund company now holds 3,545 shares of CBPO which is valued at $427,350. China Biologic Products Inc makes up approx 0.06% of Navellier Associates Inc’s portfolio.
China Biologic Products Inc opened for trading at $112.2 and hit $113.5 on the upside on Monday, eventually ending the session at $112.08, with a gain of 0.05% or 0.06 points. The heightened volatility saw the trading volume jump to 2,68,765 shares. Company has a market cap of $3,014 M.
On the company’s financial health, China Biologic Products Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $1.18. The company had revenue of $91.42 million for the quarter, compared to analysts expectations of $87.58 million. The company’s revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS.
China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).